Details

Autor(en) / Beteiligte

• Iwanami, Shoya
• Ejima, Keisuke
• Kim, Kwang Su
• Noshita, Koji
• Fujita, Yasuhisa
• Miyazaki, Taiga
• Kohno, Shigeru
• Miyazaki, Yoshitsugu
• Morimoto, Shimpei
• Nakaoka, Shinji
• Koizumi, Yoshiki
• Asai, Yusuke
• Aihara, Kazuyuki
• Watashi, Koichi
• Thompson, Robin N
• Shibuya, Kenji
• Fujiu, Katsuhito
• Perelson, Alan S
• Iwami, Shingo
• Wakita, Takaji
• Kretzschmar, Mirjam E. E.

Titel

Detection of significant antiviral drug effects on COVID-19 with reasonable sample sizes in randomized controlled trials: A modeling study

Ist Teil von

• PLoS medicine, 2021-07, Vol.18 (7), p.e1003660-e1003660

Ort / Verlag

San Francisco: Public Library of Science

Erscheinungsjahr

2021

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Development of an effective antiviral drug for Coronavirus Disease 2019 (COVID-19) is a global health priority. Although several candidate drugs have been identified through in vitro and in vivo models, consistent and compelling evidence from clinical studies is limited. The lack of evidence from clinical trials may stem in part from the imperfect design of the trials. We investigated how clinical trials for antivirals need to be designed, especially focusing on the sample size in randomized controlled trials. A modeling study was conducted to help understand the reasons behind inconsistent clinical trial findings and to design better clinical trials. We first analyzed longitudinal viral load data for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) without antiviral treatment by use of a within-host virus dynamics model. The fitted viral load was categorized into 3 different groups by a clustering approach. Comparison of the estimated parameters showed that the 3 distinct groups were characterized by different virus decay rates (p-value < 0.001). The mean decay rates were 1.17 d.sup.-1 (95% CI: 1.06 to 1.27 d.sup.-1 ), 0.777 d.sup.-1 (0.716 to 0.838 d.sup.-1 ), and 0.450 d.sup.-1 (0.378 to 0.522 d.sup.-1) for the 3 groups, respectively. Such heterogeneity in virus dynamics could be a confounding variable if it is associated with treatment allocation in compassionate use programs (i.e., observational studies). In this study, we found that estimated association in observational studies can be biased due to large heterogeneity in viral dynamics among infected individuals, and statistically significant effect in randomized controlled trials may be difficult to be detected due to small sample size. The sample size can be dramatically reduced by recruiting patients immediately after developing symptoms. We believe this is the first study investigated the study design of clinical trials for antiviral treatment using the viral dynamics model.